Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report

Sidney H. Kennedy, MDa,b,c,d,*; Raymond W. Lam, MDe; Susan Rotzinger, PhDa,b,c; Roumen V. Milev, MD, PhDf,g; Pierre Blier, MD, PhDh; Jonathan Downar, MD, PhDa,c; Kenneth R. Evans, PhDi,j; Faranak Farzan, PhDc,k; Jane A. Foster, PhDa,l; Benicio N. Frey, MD, PhDl; Peter Giacobbe, MDa,c; Geoffrey B. Hall, PhDl; Kate L. Harkness, PhDg; Stefanie Hassel, PhDm; Zahinoor Ismail, MDm; Francesco Leri, PhDn; Shane McInerney, MDa,b; Glenda M. MacQueen, MD, PhDm; Luciano Minuzzi, MD, PhDl; Daniel J. Müller, MD, PhDc,k; Sagar V. Parikh, MDo; Franca M. Placenza, PhDa; Lena C. Quilty, PhDc,k; Arun V. Ravindran, MD, PhDc,k; Roberto B. Sassi, MD, PhDl; Claudio N. Soares, MD, PhD, MBAb,f; Stephen C. Strother, PhDp; Gustavo Turecki, MD, PhDq,r; Anthony L. Vaccarino, PhDi; Fidel Vila-Rodriguez, MDe; Joanna Yu, PhDb; and Rudolf Uher, MD, PhDs; on behalf of the CAN-BIND Investigator Teamt

Published: February 5, 2019

Article Abstract

Objective: To report the symptomatic and functional outcomes in patients with major depressive disorder (MDD) during a 2-phase treatment trial and to estimate the value of early improvement after 2 weeks in predicting clinical response to escitalopram and subsequently to adjunctive treatment with aripiprazole.

Methods: Participants with MDD (N = 211) identified with the Montgomery-Asberg Depression Rating Scale (MADRS) and confirmed with the Mini-International Neuropsychiatric Interview were recruited from 6 outpatient centers across Canada (August 2013 through December 2016) and treated with open-label escitalopram (10-20 mg) for 8 weeks (Phase 1). Clinical and functional outcomes were evaluated using the MADRS, Quick Inventory of Depressive Symptomatology-Self-Rated (QIDS-SR), Sheehan Disability Scale (SDS), and Lam Employment Absence and Productivity Scale (LEAPS). Participants were evaluated at 8 and 16 weeks for clinical and functional response and remission. Phase 1 responders continued escitalopram while nonresponders received adjunctive aripiprazole (2-10 mg) for a further 8 weeks (Phase 2).

Results: After Phase 1, MADRS response (≥ 50% decrease from baseline) and remission (score ≤ 10) were, respectively, 47% and 31%, and SDS response (score ≤ 12) and remission (score ≤ 6) were, respectively, 53% and 24%. Response to escitalopram was maintained in 91% of participants at week 16, while 61% of the adjunctive aripiprazole group achieved MADRS response during Phase 2. Response and remission rates with the QIDS-SR were lower than with the MADRS. The LEAPS demonstrated significant occupational improvement (P < .05). Early symptomatic improvement predicted outcomes with modest accuracy.

Conclusions: This study demonstrates comparable symptomatic and functional outcomes to those of other large practical-design studies. There was a high response rate with the adjunctive use of aripiprazole in escitalopram nonresponders. Given the limited value of early clinical improvement to predict outcome, integration of clinical and biological markers deserves further exploration.

Trial Registration: ClinicalTrials.gov identifier: NCT01655706

Volume: 80

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...

Read More...